Kevorkian, 68 patient aspirin late treatment study: 96% lower progression [p=0.0005] https://c19p.org/kevorkiane
copied to clipboard
Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study
et al., Journal of Infection, doi:10.1016/j.jinf.2021.02.008
Observational study in France with 28 hospitalized patients treated with prednisone/furosemide/colchicine/salicylate/direct anti-Xa inhibitor, and 40 control patients, showing lower combined mortality, ventilation, or high-flow oxygen therapy with treatment.
|
risk of mortality, ventilation, or high-flow oxygen therapy, 95.7% lower, OR 0.04, p < 0.001, treatment 28, control 40, adjusted per study, multivariable, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in meta
analysis:
combined treatments may contribute more to the effect seen.
Kevorkian et al., 30 Jun 2021, retrospective, France, peer-reviewed, 11 authors, study period 9 January, 2020 - 30 November, 2020, this trial uses multiple treatments in the treatment arm (combined with prednisone, furosemide, salicylate, direct anti-Xa inhibitor) - results of individual treatments may vary.
Late treatment
is less effective
is less effective
kevorkian
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.